# Medtronic Receives FDA Approval for SynchroMed III Intrathecal Drug Delivery System

> fda · REPORTED · 2026-08-05

Medtronic received FDA approval for its SynchroMed III intrathecal drug delivery system for the management of chronic pain, cancer pain, and severe spasticity, offering targeted spinal delivery with fewer systemic side effects than oral medications. The system features full-body 1.5T and 3T MRI conditionality, a meaningful advance for patients requiring ongoing imaging.

About Medtronic: Medtronic is a global medical device leader whose pain therapies division develops implantable spinal cord stimulators and intrathecal drug delivery systems for patients with chronic and cancer-related pain.

- Company: Medtronic
- Sector: medical devices
- Primary source: https://news.medtronic.com/Medtronic-receives-FDA-approval-for-SynchroMed-TM-III-intrathecal-drug-delivery-system-for-chronic-pain,-cancer-pain,-and-severe-spasticity

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.